Thiazide diuretics are very useful antihypertensive agents for salt-sensitive and low-renin patients with hypertension. Low-dose thiazide diuretics are widely used as a combination with other first line drugs. The long term use of thiazide diuretics sometimes induces the abnormalities of glucose and lipid metabolism. Therefore, prediction of the antihypertensive effect of thiazide diuretics would be very important to realize the tailor-made medicine in the management of hypertension. The aim of this study is to detect the susceptible single nucleotide polymorphisms (SNPs) to the antihypertensive effect of thiazide diuretics, especially focusing on genes related to water-electrolyte absorption in the kidney. Seventy five outpatients (mean age 65.3Ϯ1.0 y.o.) with essential hypertension (EHT) taking thiazide diuretics either as monotherapy or combination therapy with other agents are assessed retrospectively. We defined as a responder (R) whose mean blood pressure was lowered by over 5 mmHg after thiazide treatment. After written informed consent, genotyping using TaqMan PCR method for thiazide sensitive Na-Cl cotransporter (TSC : 12SNPs detected by direct sequences), alpha-adducin(Gly460Trp), Naϩ/Ca2ϩ exchange transporter (NCX1 : 7SNPs), WNK1(7SNPs), WNK4(2SNPs), G protein subunit (GNB3-s : C825T) were performed. The SNPs of TSC, NCX1, WNK1 and WNK4 were detected by the direct sequence. All allele frequencies were over 5%. The comparison of polymorphisms prevalence between R and non-responder (NR) showed significant difference only in TCS C1784T (intron1) in all subjects (CC:TTϩCTϭ20:10 in NR, 40:5 in R, pϭ0.018, ORϭ4.00, CI:1.204-13.284, C allele:T alleleϭ49:11 in NR, 85:5 in R, pϭ0.013, ORϭ3.81, CI:1.253-11.627). In conclusion, newly detected TCS C1784T is a susceptible gene polymorphism to the antihypertensive effect of thiazide diuretics in patients with EHT. Thus, the prediction of blood pressure reduction by thiazide diuretic by evaluating TCS C1784T may be possible. To search for a pharmacogenomic antihypertensive response to Irbesartan (IRB) in accordance with the AT1 receptor (AT1R) a1166c polymorphisms.
OR-40 ANTIHYPERTENSIVE RESPONSE TO IRBESARTAN ACCORDING TO AT1 RECEPTOR A1166C POLYMORPHISMS. A PHARMACOGENOMIC APPROACH
Pedro Aranda, Armando Reyes-Engel, Francisco J. Aranda, Silvia Armengol, Eduardo Lopez de Novales. Hypertension Unit, Universitary Regional Hospital Carlos Haya, Malaga, Spain; Molecular Biology Department, Medecine Faculty of University of Malaga, Malaga, Spain; Medical Department, Sanofi Synthelabo, Barcelona, Spain. To search for a pharmacogenomic antihypertensive response to Irbesartan (IRB) in accordance with the AT1 receptor (AT1R) a1166c polymorphisms.
262 (62,98% women) mild-moderate essential hypertensives, nondiabetics and without evidence of target organs damage, untreated (n-73) or previously treated (but never with ACEI or ARB) were included. Mean age was: 54,8Ϯ7,3 years, mean BMI: 29,69 Ϯ 4,4 and mean BP: 163,6Ϯ15 / 102.7Ϯ8 mmHg. All patients were genotyped for the AT1R A1166C polymorphisms, by PCR and enzymatic restriction. At inclusion, 30 and 60 days follow-up we measured BMI, HR and BP (3 readings), as well as determined fasten levels of glucose, creatinine, Kϩ, uric acid,lipids and 24h microalbuminuria we determined at inclusion; while BP (3 readings per visist), HR and BMI were measured initially and at 30 and 60 days of follow-up.
After a 2-weeks washout period, all patients started with IRB 300 mgO.D. One month later, those non-responders (BP Ն 140 and/or 90 mmHg) added HCTZ 12.5 mg OD, been re-evaluated 30 days after. At inclusion not any statistically significant differences in mean ages, BMI and values of BP and biochemical parameters were found between the different polimorphisms, except for LDL-ch level, which was higher (pϽ0.05) in patients with C allele. (CCϭ171, AC:163 and AA 145 mg/dl respectively). The myocardial Naϩ/Ca2ϩ exchanger (NCX) plays an important role in the regulation of cardiac contractility, and the effects of calcium channel blockers (CCBs) on the heart is based upon regulating Ca2ϩ influx transient amplitudes. We investigated the role of genetic variance of NCX-1 gene ( NCX-1 ) in the antihypertensive response to CCBs in patients with essential hypertension.
Study subjects were 165 patients (male 81, female 84; 65.Ϯ9.6 years old) with essential hypertension who were newly prescribed CCBs. All of them were given a written informed consent. We performed direct sequence all region of exon, promotor and part of intron of NCX-1 . In consequence, we detected 15 polymorphisms including 13 single nucleotid polymorphisms (SNPs). We chose 7 SNPs, which allele frequency was above 5%. Response to CCBs was evaluated as the difference in three consecutive measurements of mean blood pressure before and after administration of CCBs.
Only C/T polymorphism in intron 1d (db SNP ID: rs2301340) showed significant correlation with the antihypertensive effect of CCB. The frequency of genotypes were CC 91%, CT 9% and TT 0%. Average declines in mean blood pressure was 9.5.Ϯ0.9mmHg in patients with C allele and 16.7Ϯ2.6mmHg in patients with T allele (pϭ0.01). After divided patients into two groups based on good responder (Response to CCBs more than 5 mmHg) and non-responder (Response to CCBs less than 5 mmHg or unchanged), frequency of T allele was significantly higher than that of C allele (pϭ0.04).
Assessment of polymorphism in NCX-1 may help to identify hypertensive patients who are responsive to CCBs therapy. 
